"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
Infasurf Patient Information including How Should I Take
In this Article
- What is calfactant (Infasurf)?
- What are the possible side effects of calfactant (Infasurf)?
- What is the most important information I should know about calfactant (Infasurf)?
- What should I discuss with my health care provider before receiving calfactant (Infasurf)?
- How is calfactant given (Infasurf)?
- What happens if a dose is missed (Infasurf)?
- What happens if an overdose is given (Infasurf)?
- What should be avoided after receiving calfactant (Infasurf)?
- What other drugs will affect calfactant (Infasurf)?
- Where can I get more information?
What should I discuss with my health care provider before receiving calfactant (Infasurf)?
To best participate in the care of your baby while he or she is in the NICU, carefully follow all instructions provided by your baby's caregivers.
How is calfactant given (Infasurf)?
Calfactant is given directly into the baby's lungs through a breathing tube. Your baby will receive this medication in a neonatal intensive care unit (NICU) or similar hospital setting.
The breathing tube is connected to a ventilator (a machine that moves air in and out of the lungs to help your baby breathe easier and get enough oxygen).
Calfactant is given as soon as possible after the baby's birth, usually within 30 minutes.
Calfactant is usually given every 12 hours for up to 3 doses.
Your baby's breathing, blood pressure, oxygen levels, and other vital signs will be watched closely during treatment with calfactant.
Additional Infasurf Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.